* Clene Inc. reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of five analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -8 cents to -6 cents per share.
* Revenue fell 27.4% to $170.00 thousand from a year ago; analysts expected $145.00 thousand.
* Clene Inc.'s reported EPS for the quarter was a loss of 6 cents.
* The company reported a quarterly loss of $10.17 million.
* Clene Inc. shares had risen by 49.7% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 3.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Clene Inc. is $5.00 This summary was machine generated from LSEG data March 13 at 02:37 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.07 -0.06 Beat
Sep. 30 2023 -0.09 -0.02 Beat
Jun. 30 2023 -0.12 -0.29 Missed
Mar. 31 2023 -0.14 -0.15 Missed
Comments